In the following video, Brenton Flynn sits down with Fool.com analyst Brendan Byrnes to discuss a topic that's gathered considerable attention in recent years: orphan drug development. In particular, they discuss the reasons for this focus, as well as an interesting scenario in which a very small patient market has become saturated with options.
Brendan Byrnes and The Motley Fool have no position in any stocks mentioned. Brenton Flynn owns shares of Sarepta Therapeutics. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
